Mark Castanares
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Nanoplatforms for cancer theranostics, Prostate Cancer Treatment and Research, Estrogen and related hormone effects, Advanced biosensing and bioanalysis techniques, RNA Interference and Gene Delivery
Most-Cited Works
- → Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain(2007)438 cited
- → Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons(2011)350 cited
- → Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)(2008)233 cited
- → Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer(2008)188 cited
- → Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization(2008)181 cited
- → Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts(2011)138 cited
- → A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts(2012)109 cited
- → Polymer–iron oxide composite nanoparticles for EPR-independent drug delivery(2016)91 cited
- → Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer(2014)57 cited
- → Evaluation of Prostate-Specific Membrane Antigen as an Imaging Reporter(2014)49 cited